STOCK TITAN

Longeveron Inc. - LGVNR STOCK NEWS

Welcome to our dedicated page for Longeveron news (Ticker: LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.

Longeveron LLC is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. Their lead investigational product candidate, LMSC, is based on a specialized cell known as a mesenchymal stem cell derived from the bone marrow of healthy young adult donors. The company's allogeneic, 'off-the-shelf' product is under investigation for chronic conditions of the elderly and other life-threatening diseases with no approved therapeutics currently available, including aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.

Rhea-AI Summary

Longeveron (NASDAQ: LGVN) reported its Q1 2024 financials, highlighting significant progress in clinical trials for its lead candidate, Lomecel-B™. Notably, the Phase 2b trial for HLHS is on track for completion by 2024 end. Data from a Phase 2a Alzheimer's trial will be presented at the 2024 Alzheimer’s Conference, showing promising results. Financials show a 96% revenue increase to $0.5 million, driven by the Bahamas Registry Trial, and an 8% reduction in operating expenses. The company raised $11.4 million in April, bolstering its cash reserves to $2.3 million, which is expected to fund operations through Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN) announced planned transitions on its Board of Directors, welcoming Richard Kender, a retired Merck executive, and nominating Dr. Roger Hajjar and Neha Motwani as new board candidates. Existing directors Joshua Hare and Ursula Ungaro are up for re-election. Jeffrey Pfeffer and Cathy Ross have resigned voluntarily. These changes aim to bring in new, experienced leaders to enhance Longeveron's therapeutic development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN) will report its first quarter 2024 financial results and provide a business update on May 14, 2024. The company, a clinical stage biotechnology firm focusing on regenerative medicines, will host a conference call and webcast at 5:00 p.m. ET the same day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) will be presenting at the Planet MicroCap Showcase on May 1-2, 2024. The presentation will take place on May 1, 2024, at 4:30 p.m. PT. Investors can register for 1x1 meetings with the company and attend the showcase in person at the Paris Hotel & Casino in Las Vegas, NV.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the closing of its warrant exercise offering and public offering, raising a total of $11.4 million in gross proceeds. The funding will be used to advance the HLHS program, including ongoing clinical trials for conditions like Alzheimer's disease and Aging-related Frailty. The Company issued new unregistered warrants to purchase up to 4,799,488 shares of Class A common stock, with gross proceeds of approximately $6.2 million from the warrant exercise offering and $5.2 million from the public offering. The net proceeds will support clinical and regulatory development, obtaining regulatory approvals, capital expenditures, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the exercise of warrants for $6.2 million gross proceeds. The company entered into agreements for the exercise of 2,399,744 shares of its Class A common stock at an exercise price of $2.35 per share. H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announces that its CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B™ in mild Alzheimer’s Disease has been accepted for a Featured Research Oral Presentation at the 2024 Alzheimer’s Association International Conference. The company will also present a poster at the conference. CEO Wa’el Hashad expresses excitement for sharing the study results at the leading forum for Alzheimer’s disease clinical investigation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) closes public offering, raising $5.2 million for clinical and regulatory development of Lomecel-B™. Board members and insiders participate in the offering. The Company also amends existing warrants to lower exercise price and extend expiration dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Longeveron Inc. announces a public offering of 2,234,043 shares of Class A common stock and warrants at $2.35 per share, aiming to raise capital for the development of cellular therapies for various conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Longeveron Inc. (LGVN) CEO updates shareholders on strategic roadmap and key priorities for 2024, focusing on regenerative medicine development. The company's lead product, Lomecel-B™, shows promise in treating Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer’s Disease, with positive trial results and FDA designations. Longeveron aims for HLHS commercialization, strategic collaborations, efficient resource management, and financial stewardship.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is Longeveron LLC known for?

Longeveron LLC is known for developing innovative cellular therapeutics for chronic life-threatening diseases.

What is LMSC?

LMSC is Longeveron's lead investigational product candidate based on a specialized mesenchymal stem cell derived from healthy young adult donors.

What kind of diseases does Longeveron focus on?

Longeveron focuses on chronic conditions of the elderly and other life-threatening diseases such as aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.

What is the unique selling point of Longeveron's products?

Longeveron's products are allogeneic, 'off-the-shelf' solutions for diseases where no approved therapeutics currently exist.

Who are the investors of Longeveron Inc.?

Investors can contact Derek Cole at Investor Relations Advisory Solutions for more information.

How can one get in touch with Longeveron LLC?

For inquiries, contact Derek Cole at Investor Relations Advisory Solutions.

What are the latest developments at Longeveron Inc.?

Stay updated with the latest news and events related to Longeveron Inc. by contacting Derek Cole at Investor Relations Advisory Solutions.

Where can I find more information about Longeveron Inc.?

For more information, visit Longeveron Inc.'s official website or contact Derek Cole at Investor Relations Advisory Solutions.

What are the current projects of Longeveron LLC?

Longeveron LLC is actively working on developing cellular therapeutics for chronic life-threatening diseases, including aging frailty syndrome, Alzheimer's disease, hypoplastic left heart syndrome, and the metabolic syndrome.

How does Longeveron's approach differ from traditional therapeutics?

Longeveron's approach involves utilizing mesenchymal stem cells from healthy young adult donors as an allogeneic, 'off-the-shelf' solution for chronic conditions with no approved therapeutics.

Longeveron Inc.

Nasdaq:LGVNR

LGVNR Rankings

LGVNR Stock Data

5.25M
Link
United States
Miami